Plasmacytoma

06/15/1990 - "BALB/c mice cured of large MOPC-315 plasmacytomas by melphalan remain deficient in their spleen T-cell functions. "
03/01/1988 - "Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan."
01/01/1987 - "BALB/c mice cured of a large MOPC-315 or MOPC-104E plasmacytoma following treatment with a low dose (2.5 mg/kg) of melphalan (L-PAM) were resistant to challenge with the other plasmacytoma but to a much lesser extent than to challenge with the autochthonous plasmacytoma. "
01/01/1987 - "Immune functions and hematopoietic progenitor cell activity in plasmacytoma-bearing mice cured by melphalan."
06/01/1991 - "P388D1 mouse plasmocytoma cells lacking receptors were much more sensitive to melphalan than the conjugate. "

02/01/1964 - "STUDIES OF MOUSE PLASMA CELL TUMOR AND HUMAN MYELOMA RESPONSIVENESS TO CYCLOPHOSPHAMIDE (CYTOXAN)."
08/01/1988 - "We have analyzed the expression of cyclophosphamide (CY) resistance in somatic cell hybrids of mouse LPC-1/CY-R plasmacytoma and P3-X63-Ag8.653 (Ag8) myeloma cells. "
12/01/1985 - "Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment."
06/01/1985 - "When hepatotoxicity was induced in BALB/c mice bearing the NMF-resistant ADJ/PC6A plasmacytoma, cyclophosphamide fully maintained its antitumour effect. "
07/01/1982 - "Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line."

02/01/2009 - "It has also been reported that bortezomib is effective for solitary extramedullary plasmacytoma (EMP). "
08/01/2006 - "This report lends support to the efficacy of bortezomib in the treatment of plasmacytoma and describes the safe use of bortezomib despite hepatic upset."
05/01/2009 - "These results lend support to the efficacy of bortezomib in the treatment of plasmacytoma. "
05/01/2008 - "Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas."
09/01/2002 - "In this study, we examined the efficacy, toxicity, and in vivo mechanism of action of PS-341 using a human plasmacytoma xenograft mouse model. "

01/01/1994 - "The present study was designed to examine the kinetics and function of peritoneal exudate cells (PEC) during local interleukin 2 (IL-2) gene therapy of the X63-Ag8.653 plasmacytoma growing in the peritoneal cavity. "
01/01/2010 - "We present the case of a 47-year-old man with an extremely aggressive extramedullary plasmacytoma of the lung with associated cutaneous lesions, whose disease was accompanied by a significantly decreased number of NK cells (CD56+, CD16+, CD3-) in the peripheral blood, very low NK cell activity levels, and a decreased interleukin-2 production from cultured cells in vitro. "
02/01/1998 - "In vivo adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma."
01/01/1998 - "Two murine plasma cell tumor lines, S107 and X24, were infected with a retroviral vector expressing the human IL-2 gene, and the antitumor potential of IL-2-expressing infectants was characterized in syngeneic BALB/c and BALB/c nu/nu mice. "
01/01/1997 - "As a source of IL-2, supernatants from in vitro cultured plasmacytoma cell line X63-m-IL2 secreting constitutively recombinant murine IL-2 were utilized. "

01/01/2023 - "Solitary plasmacytoma of the sacrum treated with microwave ablation in conjunction with high dose of dexamethasone: A case report and review of the literature."
06/01/2015 - "We report a case of plasmacytoma within the medial rectus muscle, which regressed completely with localized infiltration of dexamethasone. "
06/01/2015 - "Isolated extraocular muscle infiltration with plasmacytoma treated with localized injection of dexamethasone."
11/01/1992 - "The effects of dexamethasone, dibutyric-(DB)-cAMP and phorbol-12-myristate-13-acetate (TPA) have been studied on plasmacytoma cell line U266, B cell line BMNH and monocytoid cell line U937. "
01/01/2023 - "Plasmacytomas of bone can be occasionally successfully managed with MWA, adjuvant cytoreduction therapy, and high doses of dexamethasone."

09/01/2014 - "In these cases, lenalidomide has been speculated to activate cytotoxic T cells to control the plasmacytoma. "
08/01/2014 - "The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide."
08/01/2011 - "A 60-year-old patient received lenalidomide in 3-weeks-cycles for the treatment of a plasmocytoma. "
11/01/2015 - "The patient achieved partial clinical remission without any severe therapy-associated toxicity effects, indicating that lenalidomide is an effective and safe treatment for extramedullary liver plasmacytoma in renal recipients. "
11/01/2015 - "Successful treatment with lenalidomide of secondary multiple myeloma with extramedullary liver plasmacytoma in a renal transplant recipient: A case report and review of the literature."

09/01/2019 - "Improved clonality analysis based on immunoglobulin kappa locus for canine cutaneous plasmacytoma."
04/01/2011 - "In this study, we produced polyclonal rabbit anti-murine plasmacytoma cell immunoglobulin (PAb) by immunizing rabbits with the murine plasmacytoma cell line MPC-11. "
09/01/2023 - "On further investigations like immunohistochemistry, bone marrow biopsy, quantitative immunoglobulin, immunoelectrophoresis, and urine analysis, diagnosis of extraosseous plasmacytoma was made. "
08/01/2021 - "Gastric Plasmacytoma with Immunoglobulin Lambda Light Chain Deposition in a Dog."
07/01/2021 - "the solitary plasmacytomas entities characterized by the neoplastic proliferation of a single clone of plasma cells, typically producing a monoclonal immunoglobulin. "

02/01/1978 - "It is suggested that middle-aged men with an obscure progressive sensorimotor neuropathy, a raised CSF protein, and otherwise negative investigations should have a full skeletal survey since irradiation of a plasmacytoma may lead to a considerable improvement in the associated neurological disability."
10/04/1977 - "The MPC 11 mouse plasmacytoma cell line used in these studies synthesizes a glycosylated gamma2b heavy chain which accounts for 12% of the total protein synthesis. "
02/28/1964 - "STUDIES OF MORPHOGENESIS AND PROTEIN SYNTHESIS IN THREE MOUSE PLASMA CELL TUMORS (X5563, ADJ. "
12/01/1957 - "[Sedimentation analysis & electrophoretic studies of proteins in plasmocytoma]."
01/01/1954 - "[Protein studies and clinical observations in plasmocytoma patients]."

01/01/1988 - "Both new compounds exceed cisplatin considerably in their action on plasmacytoma MOPC-406 and in complete cure of mice. "
03/01/1977 - "Since, in the past, results of therapeutic trials in plasma cell tumors in humans have paralleled results in this animal model, clinical trials of cis-dichlorodiammineplatinum in multiple myeloma appear warranted."
09/01/2000 - "We investigated the mechanisms responsible for the induction of antitumor immunity in mice bearing MOPC-104E plasmacytoma after chemotherapy with cisplatin (CDDP), especially the effects of CDDP on the expression of MHC on the tumor surface. "
09/01/2000 - "Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface."
01/01/2019 - "This study aimed to explore the role and mechanism of long noncoding RNA plasmacytoma variant translocation 1 (PVT1) in cisplatin sensitivity of NSCLC. "

12/01/1963 - "[IMMUNO-ELECTROPHORETIC STUDIES OF THE PARAPROTEINS IN PLASMOCYTOMA]."
01/15/2022 - "[Detection of paraprotein in plasma cell tumors]."
01/01/2021 - "Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up."
09/01/2008 - "This case report describes a patient with a solitary extramedullary plasmacytoma involving the pleura, and no evidence of serum, urine or pleural fluid paraproteins. "
09/01/2001 - "Renal plasmacytoma is rare and should be suspected when paraprotein is detected in blood and urine, and when the patient has a history of plasmatic cell dyscrasia. "

04/20/2016 - "Subsequently, the patient achieved a sustained complete remission, after receiving palliative radiotherapy to a symptomatic gastric plasmacytoma. "
06/01/2012 - "Complete remission of localised gastric plasmacytomas following definitive radiotherapy."
07/01/2017 - "Solitary iris plasmacytoma can be successfully treated with plaque radiotherapy."
07/01/2006 - "The gold standard of treatment for plasmocytoma is its total removal and adjuvant radiation therapy; however, there is evidence for good results when it is partially removed and undergoes radiotherapy or after radical surgery without subsequent radiation. "
06/01/1989 - "This review of 84 cases of solitary plasmacytoma of the spine confirms the significantly greater survival of patients with solitary plasmacytoma, and supports the use of radiotherapy as the treatment modality of choice."

10/01/2009 - "A 66 year-old woman was diagnosed of a cranial base solitary plasmacytoma and treated with radio and chemotherapy with complete remission. "
01/01/2019 - "Localized radiation to the thigh accompanied with a change in chemotherapy improved his symptoms and a significant reduction in size of plasmacytoma was observed. "
07/01/2005 - "We report two unique cases of PTLD (CNS and plasmacytoma-like) treated successfully with salvage chemotherapy, mini-BEAM chemotherapy, and autologous stem-cell transplant. "
04/29/2014 - "The DECP chemotherapy is both effective and safe in the treatment of relapsed and refractory MM patients with extramedullary plasmacytomas."
09/01/1996 - "Previous research in our laboratories has shown that the immunoregulatory octapeptide, THF-gamma 2, potentiates the efficacy of anticancer chemotherapy in experimental animal models of local plasmacytoma and repairs drug-induced defects in immunocompetence. "

12/01/2022 - "Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group."
12/01/2008 - "These studies suggest that the defects in the B cell and blood DC pool is present in MGUS and plasmacytoma as well as patients with MM and can recover following therapy."
01/01/2024 - "We report a case of 65 years old female patient with solitary bone plasmacytoma of mandible, who has undergone surgical treatment without adjuvant therapy, with a good clinical and radiological outcomes at 12 months follow-up."
12/01/2023 - "For those patients with a dominant plasmacytoma, first-line therapy is irradiation. "
01/01/2023 - "In this report, we present a case of a patient with PCL history, treated with multiple therapeutic lines including CAR-T therapy, who presented bilateral orbital plasmacytomas as the first sign of extramedullary progression after the treatment. "

07/01/2009 - "Solitary plasmocytoma: improvement in critical organs sparing by means of helical tomotherapy."
01/01/2012 - "The role of helical tomotherapy in the treatment of bone plasmacytoma."
07/01/2009 - "Helical tomotherapy (HT) was assessed in two patients with paramedullar solitary bone plasmocytoma. "
06/28/2013 - "To assess the feasibility of the combination of helical tomotherapy(®) (HT) and a concurrent systemic targeted therapy in patients with solitary plasmacytoma (SP) with the aim to decrease toxicity while improving therapeutic efficacy. "
06/28/2013 - "Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study."

01/01/1986 - "Polychemotherapy has improved prognostic parameters of survival in patients with plasmocytoma. "
12/01/2001 - "The purpose of this study is to report an extremely rare case of solitary bone plasmacytoma with a mandibular localization treated with radio- and polychemotherapy."
04/01/1993 - "In our patient, this was possible for the pancreatic plasmocytoma, whereas the hepatic lesion was first treated with general polychemotherapy because of the tumour size and adverse prognostic factors. "
10/01/1991 - "Therefore polychemotherapy was given, during which complete macroscopic and microscopic regression of the laryngeal plasmacytoma was observed. "
11/01/1999 - "The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and then developed plasmacytoma in the same lesion. "